Search Bar & Filters
Found 19 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.
Actively Recruiting
Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.
Actively Recruiting
This research aims to evaluate the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people recently implanted with this device for resistant hypertension. The study observes patients implanted under the CE-Marked indication to assess how the therapy works in a commercial setting. The registry includes participants implanted within the past 30 days who meet specific blood pressure and medication resistance criteria. Participants in this registry have the BAROSTIM NEO System implanted and are followed over time without additional treatment interventions, as this is an observational study. Data are collected from standard medical care measurements taken before implantation, at enrollment, and at 3, 6, and 12 months after implantation. After the first year, data collection continues every six months for up to three years, providing long-term observation of therapy impact. During the study, participants undergo regular assessments of blood pressure, changes in cardiovascular medications, and health care use from before implant through three years post-implant. Researchers collect this information during routine care visits, and participants remain under usual medical supervision. The total participation duration can be up to three years from implantation, with data collected at scheduled intervals to monitor the therapys ongoing effects.
Actively Recruiting
Researchers are collecting data in a registry study for adults diagnosed with acute myeloid leukemia AML, including newly diagnosed and relapsed cases. The study aims to gather important information about the diseases epidemiology, such as patient age and prognostic factors, and to compare incidence and age distribution with population tumor registry data. It also evaluates key clinical outcomes like relapse-free survival, time to relapse, cumulative incidence of relapse, and overall survival. This observational study does not involve treatment assignment but documents treatment strategies used by patients. Data is gathered over a 10-year period to thoroughly monitor outcomes and disease patterns. The registry also collects information on complete remission rates, treatment-related mortality, therapy-associated morbidity, and quality of therapy and diagnosis. Additionally, the study seeks to validate known prognostic factors and explore new ones while describing new therapies and supportive care measures. Participants are adults aged 18 years and older diagnosed with AML according to WHO criteria, including acute promyelocytic leukemia. The study involves long-term follow-up with yearly assessments over 10 years. Researchers will evaluate epidemiological parameters and important survival outcomes. Since this is an observational registry, participants continue with their usual care while data is collected. The study is sponsored by Technische Universitt Dresden and involves multiple sites in Germany.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of combining two drugs, loncastuximab tesirine and epcoritamab, in patients with relapsed or refractory aggressive B-cell lymphoma, including diffuse large B-cell lymphoma DLBCL, high-grade B-cell lymphoma HGBL, and follicular lymphoma grade 3B. The study includes patients who have not received CAR-T cell therapy but failed first-line treatment, as well as those who have had CAR-T therapy and experienced failure. This is a phase II clinical trial aiming to assess toxicity and response rates in these patient groups. Participants receive loncastuximab tesirine intravenously with an initial dosing schedule followed by maintenance doses every 21 days in responding patients for up to six cycles. Epcoritamab is given as a subcutaneous injection with a step-up dosing during the first cycle, then weekly in cycles 2 and 3, biweekly in cycles 4 to 9, and monthly from cycle 10 to a maximum of 13 cycles. The trial includes a safety analysis after 20 patients start treatment and an interim efficacy analysis after 50 patients are recruited, with additional response assessments for CAR-T naive patients. During the study, participants undergo regular assessments including imaging by FDG-PETCT or MRI to evaluate tumor response, laboratory tests for organ function, and monitoring of adverse events up to 150 days after the last drug administration. The primary outcome is the best overall response rate measured 12 months after starting therapy. Secondary outcomes include progression-free and overall survival, response duration, and treatment-related safety events. The trial may last until April 2030, with 120 participants expected to be enrolled.
Actively Recruiting
Researchers are evaluating the efficacy and safety of two doses 2 gday and 3 gday of oral controlled-ileocolonic-release nicotinamide CICR-NAM compared to placebo in adults with mild to moderately active ulcerative colitis UC. This trial aims to improve intestinal inflammation by increasing nicotinamide supply in the ileocolonic region to positively influence the gut microbiota. The study is a double-blind, randomized, placebo-controlled phase IIIII trial. Participants are randomly assigned to one of three groups receiving either 2 gday CICR-NAM, 3 gday CICR-NAM, or placebo, taking six tablets daily to maintain blinding. The study includes a 12-week induction period followed by a 40-week maintenance period, resulting in 52 weeks of treatment. An optional open-label arm with 3 gday CICR-NAM is available for patients who complete induction but experience worsening disease. During the study, participants will take assigned tablets daily and attend visits for assessments. Researchers will monitor symptomatic remission at 12 weeks and clinical remission at 52 weeks. Evaluations include disease activity scores, endoscopy, and laboratory tests. Safety and treatment effects will be continuously monitored throughout the year-long trial. Participants adherence and response to treatment will be carefully tracked.
Actively Recruiting
This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.
Actively Recruiting
Researchers are studying a medicine called elranatamab to treat multiple myeloma MM, a type of cancer. This study compares elranatamab with other common combination therapies for people with MM that has returned or not responded to previous treatments, including anti-CD38 antibody and lenalidomide. The study is sponsored by Pfizer and is a phase 3, open-label trial evaluating treatment options for adults with relapsed or refractory MM. Participants will be randomly assigned to receive either elranatamab alone or one of several combination therapies chosen by the study doctor. Elranatamab is given as a shot under the skin at the clinic about once a week, which may reduce in frequency later. Combination therapies include two to three different medicines taken orally or by injection at the clinic, with dosing schedules depending on the selected regimen. Treatment continues until the disease no longer responds. During the study, participants will have regular clinic visits to monitor their response and safety while receiving treatment. After treatment ends, follow-up will be done by phone or clinic visits. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, duration of response, and quality of life over approximately five years. Safety and laboratory tests will also be monitored throughout and shortly after treatment completion.
Actively Recruiting
Researchers are evaluating whether patients with hormone-receptor positive, HER2-negative early breast cancer HRHER2- eBC who have intermediate to high risk of recurrence may benefit from an initial 5-year treatment with elacestrant, with or without a CDK 46 inhibitor, followed by standard endocrine therapy ET for an additional 0 to 2.5 years. This is compared to the current standard of care ET lasting between 5 and 7.5 years, with or without CDK 46 inhibitors. The study is designed for patients identified by genomic tests like Oncotype DX and response to preoperative endocrine therapy, aiming to improve long-term survival by targeting resistance mechanisms such as ESR1 mutations. Participants are randomly assigned to one of two groups one receiving elacestrant orally for 5 years, possibly combined with ribociclib a CDK 46 inhibitor for 3 years if indicated, and the other receiving standard endocrine treatments for 5 to 10 years with optional CDK 46 inhibitors as decided by their doctor. The treatments are evaluated in a parallel study design. The trial builds on previous findings in metastatic breast cancer and early breast cancer studies exploring endocrine therapy responses and genomic risk assessments. Throughout the study, participants undergo regular clinical assessments, including tumor pathology reviews, laboratory tests, and electrocardiograms to monitor safety and treatment effects. Researchers measure outcomes such as 5-year invasive disease-free survival and other survival metrics. Participants must comply with contraception requirements and be followed for treatment adherence and safety until study completion, which is planned for up to 2033.
Actively Recruiting
Triple negative breast cancer TNBC is a type of breast cancer that lacks certain receptors and tends to have a poor prognosis and aggressive behavior. The study focuses on patients with low-risk, early-stage TNBC stage I-II node-negative who generally have better outcomes, but still face significant clinical challenges. Researchers are evaluating neoadjuvant therapies to improve treatment strategies for this group, especially comparing sacituzumab govitecan alone versus its combination with pembrolizumab. Participants will receive neoadjuvant treatment for 12 weeks, either sacituzumab govitecan alone or combined with pembrolizumab. Sacituzumab govitecan is given intravenously at 10 mgkg on Days 1 and 8 every 21 days, while pembrolizumab is administered intravenously at 200 mg every three weeks. Depending on their response after 12 weeks, some patients may continue treatment for an additional 6 weeks before surgery. Patients who achieve a complete response may not require further systemic treatment, while those with residual disease may receive additional chemotherapy as decided by their investigator. Throughout the study, participants will be closely monitored with various assessments including pathological evaluation at surgery and invasive disease-free survival measured after three years. Other outcomes include overall survival and quality of life assessments. Safety and response will be regularly evaluated to guide treatment decisions. The trial aims to enroll adult women with early-stage TNBC and will continue through September 2029, with detailed follow-up planned to capture long-term outcomes.
1-10 of 19
1